Mandats représentatifs
Life Sciences team advises Nanexa on a EUR 1.165 billion global licence and collaboration agreement with Novo Nordisk
2
Our Life Sciences team has advised Nanexa AB (publ) (Nanexa) on a EUR 1.165 billion global licence and collaboration agreement with Novo Nordisk (Novo) for the use of Nanexa's proprietary PharmaShell® drug delivery technology platform.
The deal sees Nanexa grant Novo a global exclusive licence to use its PharmaShell® platform for the development of certain peptide-based drugs targeting obesity, type 2 diabetes and other cardiometabolic conditions. It covers up to five development programmes and the development of long-acting injectable formulations with different administration frequencies. Novo will lead the global development and commercialisation of products developed under the agreement.
Under the deal's terms, Nanexa is eligible to receive upfront consideration and milestone payments totalling up to EUR 1.165 billion. This includes EUR 615 million in upfront consideration and potential development and regulatory milestone payments. The agreement also includes single-digit royalties payable to Nanexa on future product sales.
Gowling WLG's Co-leader of Life Sciences & Healthcare (UK) Gina Bicknell and Of Counsel Pat Duxbury jointly led the deal. They worked closely with Nanexa's Chief Executive Officer, David Westberg, and Chief Business Officer, Bridget Lacey.
Gina Bicknell said: "This is a significant strategic agreement for our client, Nanexa, bringing together its innovative drug delivery technology with Novo's expertise in treating obesity and type 2 diabetes. Our established relationship with Nanexa, built up over a number of years, enabled us to act as one team and ensure the commercial outcomes of the deal met their key priorities and worked for all parties.
"We are pleased to help them accelerate the advancement of new treatments in this important and rapidly advancing field."
Nanexa is a Swedish-headquartered drug development company, specialising in developing injectable drug products using its proprietary PharmaShell® drug delivery technology. Founded in 2007, Nanexa focuses on long-acting injectables and collaborates with a number of major pharmaceuticals through partnerships and licensing agreements. In addition to this latest deal, Gowling WLG also advised Nanexa on its licence and option agreement with Moderna in 2025 for the development of PharmaShell®-based products.
Gowling WLG's Life Sciences team combines deep sector knowledge with first-hand scientific and industry experience to help clients navigate complex legal, regulatory and commercial challenges. Advising innovative companies at every stage of growth, from emerging biotechs to established global pharmaceutical businesses, the team helps clients navigate complex legal and commercial issues while advancing the next generation of healthcare and life sciences innovation. Recognised as one of the UK's leading life sciences practices, the team is valued for its technical understanding, commercial insight and collaborative approach.
CECI NE CONSTITUE PAS UN AVIS JURIDIQUE. L'information qui est présentée dans le site Web sous quelque forme que ce soit est fournie à titre informatif uniquement. Elle ne constitue pas un avis juridique et ne devrait pas être interprétée comme tel. Aucun utilisateur ne devrait prendre ou négliger de prendre des décisions en se fiant uniquement à ces renseignements, ni ignorer les conseils juridiques d'un professionnel ou tarder à consulter un professionnel sur la base de ce qu'il a lu dans ce site Web. Les professionnels de Gowling WLG seront heureux de discuter avec l'utilisateur des différentes options possibles concernant certaines questions juridiques précises.
